Unveiling the Mechanism of Compound Ku-Shen Injection in Liver Cancer Treatment through an Ingredient-Target Network Analysis.

ABSTRACT:

Background

Compound Ku-Shen Injection (CKI) is a traditional Chinese medicine preparation derived from Ku-Shen and Bai-Tu-Ling, commonly used in the adjunctive treatment of advanced cancers, including liver cancer. However, the underlying mechanisms of CKI's effectiveness in cancer treatment are not well defined.

Methods

This study employs network pharmacology to investigate the traditional Chinese medicine (TCM) compatibility theory underlying CKI's action in treating liver cancer, with findings substantiated by molecular docking and in vitro experiments. Sixteen active components were identified from CKI, along with 193 potential targets for treating liver cancer. Key therapeutic target proteins, including EGFR and ESR1, were also identified. KEGG enrichment results showed

SUBMITTER: Zou W 

PROVIDER: S-EPMC11507192 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature